Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives

Communicating About Chemotherapy-Induced Nausea and Vomiting: A Comparison of Patient and Provider Perspectives

(2017) John M. Salsman et al.   Journal of the National Comprehensive Cancer Network

Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone

(2013) Corinna Lanzarotti et al.   SUPPORTIVE CARE IN CANCER

Supportive care

(2012) S. Clarke et al.   ANNALS OF ONCOLOGY

Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects

(2012) Marigo Stathis et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting

(2012) Camilo Rojas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant

(2012) Anna Rizzi et al.   PEPTIDES

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Update and new trends in antiemetic therapy: the continuing need for novel therapies

(2010) P. Feyer et al.   ANNALS OF ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Aprepitant: drug-drug interactions in perspective

(2010) M. S. Aapro et al.   ANNALS OF ONCOLOGY

Ketoconazole and Rifampin Significantly Affect the Pharmacokinetics, But Not the Safety or QTc Interval, of Casopitant, a Neurokinin-1 Receptor Antagonist

(2010) Brendan M. Johnson et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo

(2010) C. Rojas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

(2009) Mitsue Saito et al.   LANCET ONCOLOGY

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

(2009) Brendan Johnson et al.   SUPPORTIVE CARE IN CANCER

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron

(2009) Laurel M. Adams et al.   SUPPORTIVE CARE IN CANCER